The Progressive Multifocal Leukoencephalopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Progressive Multifocal Leukoencephalopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Progressive Multifocal Leukoencephalopathy by 11 companies/universities/institutes. The top development phase for Progressive Multifocal Leukoencephalopathy is preclinical with four drugs in that stage. The Progressive Multifocal Leukoencephalopathy pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Progressive Multifocal Leukoencephalopathy pipeline products market are: Neurimmune, Biological E and Merck.

The key targets in the Progressive Multifocal Leukoencephalopathy pipeline products market include Major Capsid Protein VP1 (JC Polyomavirus Major Structural Protein VP1), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2).

The key mechanisms of action in the Progressive Multifocal Leukoencephalopathy pipeline product include Major Capsid Protein VP1 (JC Polyomavirus Major Structural Protein VP1) Inhibitor with two drugs in Discovery. The Progressive Multifocal Leukoencephalopathy pipeline products include seven routes of administration with the top ROA being Subcutaneous and six key molecule types in the Progressive Multifocal Leukoencephalopathy pipeline products market including Monoclonal Antibody, and Small Molecule.

Progressive Multifocal Leukoencephalopathy overview

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by polyomavirus, also known as JC (John Cunningham) virus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JC virus and an altered or weakened immune system, and genetic or environmental factors.

For a complete picture of Progressive Multifocal Leukoencephalopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.